Narrative review / 2002
The clinical effectiveness of soy protein may depend on an individual's ability to produce the metabolite equol from daidzein.
This review examines the biology, formation, and clinical data regarding equol, a nonsteroidal estrogen produced exclusively by intestinal bacteria from the soy isoflavone daidzein. Equol possesses affinity for estrogen receptors ERalpha and ERbeta and exhibits superior antioxidant activity compared to other isoflavones. Because equol is not produced in all adults, maximal clinical responses to soy diets in cardiovascular, bone, and menopausal health are seen in 'equol-producers.' The authors propose that classifying individuals by their equol-producing status could explain historical variance in soy intervention outcomes.
- Study type
- Narrative review
- Who was studied
- Healthy adults and clinical study participants
- What was measured
- Equol production and clinical effectiveness of soy diets
THE PAPER
The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones.
Setchell KD, Brown NM, Lydeking-Olsen E. J Nutr, 2002.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.